Replimune Group, Inc.
$9.98
+13%Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -3.3).
Valuation inputs: P/E -3.3, earnings yield N/A, momentum +12.5%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -59.5%, ROIC -53.1%).
Profitability stack: net margin 0.0%, ROE -59.5%, ROIC -53.1%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +24.6%, momentum +12.5%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Replimune Group, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Replimune Group, Inc. Fair Value Envelope
No Revenue Data
REPL has not reported any revenue values in the available annual periods.
Replimune Group, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
REPL has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
REPL has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
REPL has not reported any net profit margin values in the available annual periods.
Replimune Group, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Replimune Group, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Replimune Group, Inc. Street Expectations Map
Wall Street analysts project that REPL stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 14.00, with estimates ranging from a low of 14.00 to a high of 14.00.
The consensus 1-year price target stands at 14.00, with estimates ranging from a low of 14.00 to a high of 14.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Replimune Group, Inc. Insider Positioning
During the last 12 months, insiders have sold $944K worth of REPL shares, with no buying activity reported.
3 Months
0
0.00
111.8K
637.09K
-637K
-$637K
3-6 Months
0
0.00
3.2K
32.96K
-33K
-$33K
6-9 Months
0
0.00
22.5K
224.65K
-225K
-$225K
9-12 Months
0
0.00
9.2K
49.16K
-49K
-$49K
Top Buyers
No buying activity
Top Sellers
Patel Sushil
Director, Officer: Chief Executive Officer
$301K
Sarchi Christopher
Officer: Chief Commercial Officer
$254K
Xynos Konstantinos
Officer: Chief Medical Officer
$137K
Astley-Sparke Philip
Director
$90K
Hill Emily Luisa
Officer: Chief Financial Officer
$89K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $944K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
REPL has not reported any dividend yield values in the available annual periods.
repl Dividend History
Learning Layer
Related Guides
Build conviction on REPL by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.